Atagabalin
From Infogalactic: the planetary knowledge core
![]() |
|
Systematic (IUPAC) name | |
---|---|
[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
|
|
Identifiers | |
CAS Number | 223445-75-8 ![]() |
ATC code | none |
PubChem | CID: 9794485 |
ChemSpider | 7970252 ![]() |
UNII | JT7957Q2FB ![]() |
ChEMBL | CHEMBL593430 ![]() |
Chemical data | |
Formula | C10H19NO2 |
Molecular mass | 185.263 g/mol |
|
|
|
|
![]() ![]() |
Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2).[1] It was under development as a treatment for insomnia,[2][3][4] but was discontinued following unsatisfactory trial results.
See also
References
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Abandoned drugs
- Amino acids
- Calcium channel blockers
- GABA analogues
- Hypnotics
- Pfizer
- Sedative stubs